Coherus BioSciences Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd. announced positive interim results from a phase 3 clinical trial, which evaluated toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer or NSCLC.
The interim analysis from the pivotal study "CHOICE-01" (NCT03856411) met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival per RECIST v1.1 compared to chemotherapy alone.
The interim results will be presented on September 13 at IASLC 2021 World Conference on Lung Cancer.
The company expects to pursue registration for toripalimab for a broad array of indications in China, the United States and other markets.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.